RECRUITING

Treatment of Tinnitus With Migraine Medications

Talk to us

Conditions

Tinnitus, SubjectiveTinnitusmedicationrandomizedRCTtrialmigraine

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Tinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. It is well-understood that many factors, such as poor education, lower income, or occupational, and recreational activity associated with high noise exposure, influences the prevalence and risk of tinnitus. Although the economic and emotional impact of tinnitus is large, there is currently no FDA-approved medication to treat this condition. However, there are pharmacological options to address the stress, anxiety, and depression that are caused by tinnitus. In this project, we intend to use medications for patients with tinnitus in order to decrease the impact of tinnitus on their daily life and activities.

Official Title

Treatment of Tinnitus With Migraine Medications: A Randomized Clinical Trial

Quick Facts

Study Start:2019-09-26
Study Completion:2023-12-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04404439

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:25 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients with moderate to severe tinnitus.
  2. * Male or female between the ages of 25 to 85 years.
  3. * Subject must be compliant with the medication and attend study visits.
  4. * Must be able to read and write in the English language to provide consenting.
  1. * Pregnancy will result in automatic exclusion from the study. Rule out of pregnancy will be done by a urine pregnancy test to confirm the situation for all women who are of child bearing potential.
  2. * Subject with history of an adverse reaction to medication being prescribed.
  3. * Subject suffers from a medical condition or has history that may be concerning to the investigators clinical opinion.
  4. * All contraindications for the medications which prevent subjects from randomization will be considered as exclusion criteria.

Contacts and Locations

Study Contact

Hamid R Djalilian, MD
CONTACT
800-263-9547
hdjalili@hs.uci.edu

Principal Investigator

Hamid R Djalilian, MD
PRINCIPAL_INVESTIGATOR
Univeristy of California, Irvine

Study Locations (Sites)

University of California, Irvine Medical Center ENT Clinic (Pavilion 2)
Orange, California, 92868
United States

Collaborators and Investigators

Sponsor: University of California, Irvine

  • Hamid R Djalilian, MD, PRINCIPAL_INVESTIGATOR, Univeristy of California, Irvine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-09-26
Study Completion Date2023-12-30

Study Record Updates

Study Start Date2019-09-26
Study Completion Date2023-12-30

Terms related to this study

Keywords Provided by Researchers

  • tinnitus
  • medication
  • randomized
  • RCT
  • trial
  • migraine

Additional Relevant MeSH Terms

  • Tinnitus, Subjective
  • Tinnitus